Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release - Full Text View

Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release

This study is currently recruiting participants.
Verified by Inje University, March 2007

Sponsors and Collaborators:	Inje University GlaxoSmithKlineKorea
Information provided by:	Inje University
ClinicalTrials.gov Identifier:	NCT00492414

Purpose

Panic disorder(PD)is a disabling psychiatric condition associated with significant impairment in psychosocial, occupational functioning and quality of life, as mentioned by mogotsi et al. So, most patients with panic disorder suffers from the consequences of the impairment in occupational function. This impairment is not only individual problem, but also social one. Since productivity is very important item required to employees, lost productive time among workers with psychiatric illness should be reduced by the proper management. But few data were reported in this field by now.

Condition	Intervention	Phase
Panic Disorder	Drug: Paroxetine CR	Phase IV

MedlinePlus related topics:

Panic Disorder

ChemIDplus related topics:

Paroxetine Paroxetine hydrochloride Paroxetine Mesylate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Health Services Research, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study

Eligibility

Ages Eligible for Study:	20 Years to 50 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Male or female outpatients aged 20-50 years
In female, is eligible to enter this study if she is if
- Non-childbearing potential(note:women who are 6 months post-menopausal are not considered women of child-bearing potential)
- child-bearing potential, has a negative urine dipstick pregnancy test, and is practicing a clinically acceptable method of contraception such as oral contraception, surgical sterilization, I.U.D.,systemic contraception, or double barrier contraception(any two of diaphragm/spermicidal foar/condom)
Subject currently meets the diagnosis for PD according to korean version of Anxiety Disorder Interview Schedule for DSM-IV(ADIS-IV) through a comprehensive psychiatric evaluation and not being treated currently.
Subject must have the ability to comprehend the key components of the consent form and provide informed consent.

Exclusion Criteria:

Subject who has a history of any other major medical or psychiatric illnesses except PD or PD with major depressive disorder.
Subject who retired or left his job or who plan to retire within two years.
is a current homicidal or suicidal risk in the investigator's judgement.
is currently pregnant, lactating or planning to become pregnant within the next 3 months
is currently participating in any other clinical trial or taking any non-approved or experimental medication.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00492414

Contacts


Contact: Eun-Joo Jung	+82-2-2270-0940	menfipro@naver.com

Locations


Korea, Republic of
	Seoul Paik Hospital, Inje University	Recruiting
	Seoul, Korea, Republic of
	Contact: Eun-Joo Jung +82-2-2270-0940 menfipro@naver.com

Sponsors and Collaborators

Inje University

GlaxoSmithKlineKorea

Investigators


Principal Investigator:	Jong-Min Woo, Master	Seoul Paik Hospital, Inje University

More Information

Study ID Numbers:	COL110010
First Received:	June 26, 2007
Last Updated:	August 7, 2007
ClinicalTrials.gov Identifier:	NCT00492414
Health Authority:	South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by Inje University:

Panic disorder (PD)

Study placed in the following topic categories:

Panic Disorder

Anxiety Disorders

Mental Disorders

Paroxetine

Serotonin

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors

Neurotransmitter Agents

Disease

Molecular Mechanisms of Pharmacological Action

Physiological Effects of Drugs

Psychotropic Drugs

Serotonin Uptake Inhibitors

Pharmacologic Actions

Pathologic Processes

Serotonin Agents

Therapeutic Uses

Antidepressive Agents, Second-Generation

Central Nervous System Agents

Antidepressive Agents

ClinicalTrials.gov processed this record on August 29, 2008